High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie County stroke study

Pharmacotherapy

Volumn 26, Issue 4, 2006, Pages 493-498

  Qureshi, Adnan I ^a,c   Kirmani, Jawad F ^a   Safdar, Adnan ^a   Ahmed, Shafiuddin ^a   Sayed, Muhammad A ^b   Pande, Ravi U ^c   Ferguson, Richard ^c   Hershey, Linda A ^c   Qazi, Khalid J ^d  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Cascade Valley Sleep Disorders Center   (United States)

^c Department of Neurology ^*  (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antiplatelet therapy; Aspirin; Clopidogrel; Ischemic stroke; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; UNITED STATES;

ASPIRIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; HOSPITALIZATION; HUMANS; NEW YORK; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 33645663720     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.4.493     Document Type: Article

References (19)

1. Teal PA. Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. Cerebrovasc Dis 2004;17(suppl 3):6-10.
2. Hankey GJ. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care. Cerebrovasc Dis 2004;17(suppl 3):11-16.
3. Albers GW, Hart RG, Lutsep HL, Newell DW, Sacco RL. AHA scientific statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the ad hoc committee on guidelines for the management of transient ischemic attacks, stroke council, American Heart Association. Stroke 1999;30:2502-11.
4. Adams HP Jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Stroke Association. Stroke 2003;34:1056-83.
5. Mohr JP, Thompson JL, Lazar RM, et al, for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
6. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al, for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Group. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305-16.
7. Qureshi AI, Kirmani JF, Sayed MA, et al. Buffalo metropolitan area and Erie County stroke study: rationale, design, and methods. Neuroepidemiology 2004;23:289-98.
8. Anonymous. Special report from the National Institute of Neurological Disorders and Stroke: classification of cerebrovascular diseases III. Stroke 1990;21:637-76.
9. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-80.
10. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O'Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991;22:1236-41.
11. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 1992;23:1250-6.
12. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
13. Coull AJ, Lovett JK, Rothwell PM, for the Oxford Vascular Study Group. Population-based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004;328:326.
14. Urbinelli R, Bolard P, Lemesle M, et al. Stroke patterns in cardio-embolic infarction in a population-based study. Neurol Res 2001;23:309-14.
15. Chamorro A, Blanc R, Ascaso C, Saiz A, Vila N. Factors associated to aspirin failure for secondary stroke prevention [in Spanish]. Med Clin (Barc) 1997;109:569-72.
16. Grotta JC, Norris JW, Kamm B. Prevention of stroke with ticlopidine: who benefits most? TASS baseline and angiographic data subgroup. Neurology 1992;42:111-15.
17. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology 2000;55:490-7.
18. Broderick J, Brott T, Kothari R, et al. The greater Cincinnati/Northern Kentucky stroke study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998;29:415-21.
19. Piriyawat P, Smajsova M, Smith MA, et al. Comparison of active and passive surveillance for cerebrovascular disease: the brain attack surveillance in Corpus Christi (BASIC) project. Am J Epidemiol 2002;156:1062-9.